Singapore, Oct. 22 -- Samsung Biologics reported third-quarter revenue of KRW 1.49 trillion and operating profit of KRW 640 billion, supported by manufacturing activity in Korea and initial revenue contributions from its acquired Rockville facility in the US.

The company raised its full-year 2026 revenue growth guidance to 20%, from a previous range of 15-20%.

Plants 1 through 4 operated at full capacity, while Plant 5 contributed increasingly as production ramped up. Cumulative contract orders exceeded US$21.9 billion.

Alongside its manufacturing expansion, Samsung Biologics is pursuing the acquisition of PolyPeptide Group through its Swiss subsidiary, Samsung Peptide.

Definitive interim results showed that 87.59% of PolyPeptide shar...